Analysis of reactive oxygen species (ROS) generation and caspase-8 activation by analogues of proteasome inhibitor NPI-0052

被引：0
|
作者：
Hale, Randal
Miller, Claudia
Manam, Rama
Macherla, Venkat
Palladino, Michael
Potts, Barbara
Chandra, Joya
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5634
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NPI-0052: A Second-Generation Proteasome Inhibitor
    Spear, M. A.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S33 - S33
  • [2] Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells
    Miller, Claudia P.
    Rudra, Sharmistha
    Keating, Michael J.
    Wierda, William G.
    Palladino, Michael
    Chandra, Joya
    BLOOD, 2009, 113 (18) : 4289 - 4299
  • [3] NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
    Miller, Claudia P.
    Ban, Kechen
    Dujka, Melanie E.
    McConkey, David J.
    Munsell, Mark
    Palladino, Michael
    Chandra, Joya
    BLOOD, 2007, 110 (01) : 267 - 277
  • [4] Caspase-8 and oxidant dependent hyper-acetylation of histone-H3 by the novel proteasome inhibitor NPI-0052
    Miller, Claudia
    Rudra, Sharmistha
    Keating, Michael
    Wierda, William
    Palladino, Michael
    Chandra, Joya
    CANCER RESEARCH, 2009, 69
  • [5] Requirement of caspase-8 versus caspase-9 during apoptosis in multiple myeloma cells induced by Bortezomib -: Or a novel proteasome inhibitor NPI-0052
    Chauhan, D
    Catley, L
    Velankar, M
    Letai, A
    Hideshima, T
    Podar, K
    Yasui, H
    Mitsiades, N
    Mitsiades, C
    Tai, YT
    Raje, N
    Munshi, N
    Palladino, MA
    Anderson, KC
    BLOOD, 2005, 106 (11) : 944A - 944A
  • [6] NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Kurzrock, R.
    Hamlin, P.
    Gordon, M.
    Hong, D.
    Fu, S.
    Younes, A.
    Hannah, A.
    Palladino, M. A.
    Spear, M. A.
    Aghajanian, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 73 - 74
  • [7] Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D
    Townsend, A.
    Padrik, P.
    Mainwaring, P.
    Price, T.
    Catley, L.
    Longenecker, A.
    Palladino, M. A.
    Lloyd, G. K.
    Spear, M. A.
    Millward, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 74 - 74
  • [8] Camalexin induces apoptosis in T-leukemia Jurkat cells by increased concentration of reactive oxygen species and activation of caspase-8 and caspase-9
    Roman Mezencev
    Taylor Updegrove
    Peter Kutschy
    Mária Repovská
    John F. McDonald
    Journal of Natural Medicines, 2011, 65 : 488 - 499
  • [9] Camalexin induces apoptosis in T-leukemia Jurkat cells by increased concentration of reactive oxygen species and activation of caspase-8 and caspase-9
    Mezencev, Roman
    Updegrove, Taylor
    Kutschy, Peter
    Repovska, Maria
    McDonald, John F.
    JOURNAL OF NATURAL MEDICINES, 2011, 65 (3-4) : 488 - 499
  • [10] Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and-9 and generation of reactive oxygen species
    Kuckleburg, Christopher J.
    Tiwari, Raksha
    Czuprynski, Charles J.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 363 - 372
12345